Johnson & Johnson (NYSE:JNJ) Stock Position Reduced by Fiera Capital Corp
Fiera Capital Corp cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.6% during the third quarter, according to its most recent disclosure with the SEC. The institutional inve
Tru Independence LLC Acquires 85 Shares of Johnson & Johnson (NYSE:JNJ)
tru Independence LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund
The Use of Artificial Intelligence in Medical Devices and Drug Development
Johnson & Johnson Stock Outperforms Competitors Despite Losses On The Day
This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Johnson & Johnson (JNJ) sank 0.39% to $168.23 Friday, on what proved to be an all-around gr
Johnson & Johnson's Janssen Says Carvykti Meets Target in Late-Stage Blood Cancer Trial
12:54 PM EST, 01/27/2023 (MT Newswires) -- Johnson & Johnson (JNJ) unit Janssen Pharmaceutical said Friday its phase 3 trial assessing Carvykti against standard of care treatments for patients with re
BTIG Sees Legend Commercializing Carvykti in Earlier Lines After Study Hits Goal
Piper Keeps $78 Target on Legend Biotech After Carvykti Trial Hits
Valmark Advisers Inc. Acquires 234 Shares of Johnson & Johnson (NYSE:JNJ)
Valmark Advisers Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exch
JNJ/ Legend CAR-T Therapy Succeeds in Phase 3 Multiple Myeloma Trial
Johnson & Johnson Unit Withdraws European Application for Imbruvica Drug Combination to Treat Mantle Cell Lymphoma
08:52 AM EST, 01/27/2023 (MT Newswires) -- Johnson & Johnson's (JNJ) Janssen-Cilag International NV unit has withdrawn its European marketing application to extend the use of Imbruvica combined with b
Loading...
No Stock Yet